Lil­ly bets up to $1.9B on Ver­sanis' PhI­Ib weight loss drug alone and in com­bo with No­vo Nordisk's We­govy

Eli Lil­ly will pay up to $1.925 bil­lion in cash for weight loss drug­mak­er Ver­sa­nis, mark­ing the Big Phar­ma’s fourth ac­qui­si­tion this sum­mer af­ter deals for DICE Ther­a­peu­tics, Sig­ilon and Emer­gence Ther­a­peu­tics.

The ac­qui­si­tion could pay out in the near fu­ture, as Ver­sa­nis last month guid­ed to a Phase IIb read­out for its mon­o­clon­al an­ti­body in the mid­dle of 2024. Tri­al in­ves­ti­ga­tors are test­ing whether the as­set, dubbed bima­grum­ab, alone and in com­bi­na­tion with No­vo Nordisk’s semaglu­tide, can “sub­stan­tial­ly pre­vent the loss of mus­cle mass ob­served with semaglu­tide and oth­er in­cretin ther­a­pies” while al­so re­duc­ing fat.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER